FDA Approval: Vemurafenib (Zelboraf) for Melanoma

What FDA approved, and exactly for whom

On 17 August 2011 the FDA approved Zelboraf, the brand name for vemurafenib, under New Drug Application 202429. The sponsor was Hoffmann-La Roche.

The approval letter is precise about the population. It covers "the treatment of unresectable or metastatic melanoma with the BRAF V600E mutation as detected by an FDA-approved test."

Two conditions sit inside that sentence. The melanoma has to be one surgery cannot remove or one that has spread. And the tumor has to carry a specific gene change, confirmed by a test FDA has cleared.

The 2011 label adds a limit in the other direction: vemurafenib is not recommended for melanoma with a normal, or wild-type, BRAF gene. The label also says its efficacy and safety were never studied in that group.

The approved dose is 960 mg by mouth twice a day, taken about 12 hours apart, as 240 mg tablets.

That is the licensed reference amount. Your own melanoma team sets your dose and lowers it if the skin or joint side effects become hard to live with.

What BRAF is and why it matters

BRAF is a gene that codes for a protein in a signaling chain cells use to decide when to divide. When one letter of the gene is changed at position 600 — the V600E change — the protein gets stuck in the on position. Cells divide without being told to.

Vemurafenib is a kinase inhibitor. It blocks the stuck protein.

This is the logic of targeted therapy: the drug is aimed at a molecular fault, not at the organ the cancer started in. It is also why the test comes first. Without the V600E result, there is nothing for the drug to block. Our page on biomarker testing and precision medicine explains how those tests are ordered and read.

The trial behind it

The evidence was BRIM-3. It was a randomized phase 3 trial in 675 people with untreated metastatic melanoma carrying BRAF V600E. Half got vemurafenib. Half got dacarbazine, the chemotherapy that had been standard for decades.

At six months, overall survival was 84% in the vemurafenib group and 64% in the dacarbazine group.

At the interim survival analysis, vemurafenib cut the risk of death by 63%. It cut the risk of death or disease growth by 74%. Both figures are relative, and both had a p-value below 0.001.

Tumors shrank in 48% of the vemurafenib group and 5% of the dacarbazine group.

An independent monitoring board reviewed the interim data. It then recommended letting people on dacarbazine switch to vemurafenib. That is a strong signal on its own. It also blurs the later survival comparison, because the two groups stopped being two groups.

What it costs

Thirty-eight percent of people in BRIM-3 needed a dose change because of side effects.

The 2011 label lists what happened to 30% or more of patients. That list is joint pain, rash, hair loss, fatigue, sun sensitivity, nausea, itching, and skin papilloma.

One warning stands out. Cutaneous squamous cell carcinoma — a second, separate skin cancer — occurred in 24% of patients. The label directs a skin check before starting and every two months after. Lesions are cut out, and the drug continues.

The label flags other risks too. They include changes to the heart tracing, raised liver enzymes, serious eye problems, and new melanomas.

When to get checked

Anyone taking a BRAF inhibitor needs a skin check every two months. Any new or changing spot between visits should be reported. Sun sensitivity is expected and worth planning around.

For melanoma itself, NCI's ABCDE rule sets out what to look for on any mole:

• Asymmetry: one half does not match the other.
• Border: edges are ragged, notched, or blurred.
• Color: uneven, with shades of black, brown, and tan, and sometimes white, gray, red, pink, or blue.
• Diameter: a change in size, usually an increase. Most melanomas are wider than 6 millimeters, about a quarter inch, though they can be smaller.
• Evolving: the mole has changed over the past few weeks or months.

NCI notes that some melanomas show only one or two of these features, so any one of them is enough reason to book an appointment.

On darker skin, melanoma more often appears under a fingernail or toenail as a pigmented streak, or on a palm or sole. NCI reports that melanoma tends to be found at a later stage in people with dark skin, which makes those sites worth checking deliberately.

Where melanoma stands now

SEER, the federal cancer surveillance program, carries American Cancer Society projections of about 112,000 new melanoma diagnoses and 8,510 deaths in the United States in 2026. Five-year relative survival across all stages was 94.7% for people diagnosed from 2016 through 2022.

That high figure comes from stage: most melanoma is caught early. Only 5% is found after it has reached distant organs, and five-year relative survival in that group is 34.0%. BRIM-3 enrolled from that smallest, hardest group.

These are group statistics from a registry. They do not forecast one person's course. Our overview of melanoma covers how stage is worked out.

What this approval cannot tell you

An approval is a regulatory finding, not a promise. It says the evidence met FDA's bar for one indication in one population. It does not say the drug will help a given person.

It also does not settle sequencing. In 2011 the comparison was against dacarbazine. Melanoma care has since added checkpoint inhibitors and two-drug BRAF and MEK regimens. This approval says nothing about how vemurafenib alone compares with those.

BRIM-3 also could not answer how long the benefit lasts, because crossover was permitted after the interim analysis.

The eligibility rule is also narrow. Without a BRAF V600E result from an approved test, this approval does not apply.

Sources

• FDA approval letter, NDA 202429 (Zelboraf), 2011
• FDA label for Zelboraf, 2011
• Drugs@FDA overview for NDA 202429
• Chapman PB et al., N Engl J Med 2011, BRIM-3 (NCBI E-utilities)
• NCI: Common Moles, Dysplastic Nevi, and Risk of Melanoma
• NCI SEER Stat Facts: Melanoma of the Skin

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.